Friday 6 November 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue: +38.6%
EPS: +16.3%
Free cash flow: +21.8%
Total debt: +15.0%

Quarter to September 2026, against a year earlier

1,365.21 0.48 +0.04%

Follow LLY

Alert me

Market cap: $1.28T
P/E: 44.5×
Fwd P/E: 41.5×
Dividend yield: 0.49%
F-score: 7/9
Altman Z: 8.61
Beneish M: −1.91
Dividend safety: 86/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Eli Lilly and Company (LLY) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Eli Lilly and Company (LLY) trades at a price to free cash flow of 55.9×. Over the past ten years it has ranged from 15.8× (February 2018) to 518× (June 2024); the current reading is higher than 72% of that period. That is above the Drug Manufacturers General industry median of 21.3× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/LLY/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Eli Lilly and Company price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/LLY/metrics/price-to-free-cash-flow">Eli Lilly and Company (LLY) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	86.3×	(26.00%)
FY2024	117×	(46.13%)
FY2023	217×	281.38%
FY2022	56.8×	46.53%
FY2021	38.7×	39.60%
FY2020	27.8×	(4.46%)
FY2019	29.0×	15.38%
FY2018	25.2×	39.85%
FY2017	18.0×	(2.02%)
FY2016	18.4×	(50.70%)

Period	Price to free cash flow	Change
Sep 2026	47.2×	(10.07%)
Jun 2026	52.5×	(10.52%)
Mar 2026	58.7×	(32.03%)
Dec 2025	86.3×	44.69%
43 more quarters	Free account

Against its own ten years

Low 15.8× High 518×

Ten-year median 34.0×

Current reading's percentile 72

Company	Price to free cash flow
GILD Gilead Sciences, Inc. compare	15.1×
PFE Pfizer Inc. compare	15.5×
NVS Novartis AG compare	21.7×
MRK Merck & Co., Inc. compare	22.6×
ABBV AbbVie Inc. compare	27.1×
AMGN Amgen Inc. compare	27.3×
JNJ Johnson & Johnson compare	31.3×
AZN AstraZeneca PLC compare	45.8×
LLY Eli Lilly and Company	55.9×
Drug Manufacturers General industry median	21.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Eli Lilly and Company (LLY) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on LLY

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on LLY

Stockrow Weekly